Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDEN: Therapeutic de-escalation and miRNA-M371 evaluation in stage IIa/IIb seminoma
2024-514636-25-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin, etoposide and carboplatin in Seminomatous germ cell testicular cancer (3 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-free rate at 36 months (PFR-36m). Planned start Nov 2024; status: authorised.
02
Drugs
cisplatinetoposidecarboplatin
03
Conditions
Seminomatous germ cell testicular cancer
Beyond the preview
Go deeper on 2024-514636-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514636-25-00.